Which has preferable earnings and valuation, ONC or GSK?

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 5.69 $286.93M $4.47 62.00 GSK $43.07B 2.40 $7.54B $3.85 13.29

Is ONC or GSK more profitable?

GSK has a net margin of 17.82% compared to BeOne Medicines' net margin of 8.94%. GSK's return on equity of 44.28% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% GSK 17.82% 44.28% 11.49%

Does the media prefer ONC or GSK?

In the previous week, BeOne Medicines had 7 more articles in the media than GSK. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for GSK. GSK's average media sentiment score of 1.10 beat BeOne Medicines' score of -0.46 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral GSK 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, SNY or ONC?

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.03 $8.84B $3.58 11.54 BeOne Medicines $5.34B 5.69 $286.93M $4.47 62.00

Is SNY or ONC more profitable?

Sanofi has a net margin of 16.95% compared to BeOne Medicines' net margin of 8.94%. Sanofi's return on equity of 13.39% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% BeOne Medicines 8.94% 12.06% 6.69%

Does the media prefer SNY or ONC?

In the previous week, BeOne Medicines had 6 more articles in the media than Sanofi. MarketBeat recorded 12 mentions for BeOne Medicines and 6 mentions for Sanofi. Sanofi's average media sentiment score of 0.54 beat BeOne Medicines' score of -0.46 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ONC or ARGX more profitable?

argenex has a net margin of 31.31% compared to BeOne Medicines' net margin of 8.94%. argenex's return on equity of 44.37% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% argenex 31.31% 44.37% 37.55%

Does the media refer more to ONC or ARGX?

In the previous week, BeOne Medicines had 7 more articles in the media than argenex. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for argenex. argenex's average media sentiment score of 0.20 beat BeOne Medicines' score of -0.46 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral argenex 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TAK or ONC?

BeOne Medicines has a consensus price target of $390.00, indicating a potential upside of 40.73%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 BeOne Medicines 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.93

Does the media prefer TAK or ONC?

In the previous week, BeOne Medicines had 10 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for BeOne Medicines and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.17 beat BeOne Medicines' score of -0.46 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

BeOne Medicines (ONC) Competitors

$277.12 +0.99 (+0.36%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$273.85 -3.27 (-1.18%)

As of 06/24/2026 05:23 PM Eastern

Compare

ONC vs. GSK, SNY, ARGX, TAK, and TEVA

Should you buy BeOne Medicines stock or one of its competitors? MarketBeat compares BeOne Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BeOne Medicines include GSK (GSK), Sanofi (SNY), argenex (ARGX), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

How does BeOne Medicines compare to GSK?

BeOne Medicines (NASDAQ:ONC) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, BeOne Medicines had 7 more articles in the media than GSK. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for GSK. GSK's average media sentiment score of 1.10 beat BeOne Medicines' score of -0.46 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	62.00
GSK	$43.07B	2.40	$7.54B	$3.85	13.29

BeOne Medicines presently has a consensus price target of $390.00, suggesting a potential upside of 40.73%. GSK has a consensus price target of $53.00, suggesting a potential upside of 3.62%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
GSK	3 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

GSK has a net margin of 17.82% compared to BeOne Medicines' net margin of 8.94%. GSK's return on equity of 44.28% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
GSK	17.82%	44.28%	11.49%

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BeOne Medicines beats GSK on 10 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Sanofi?

Sanofi (NASDAQ:SNY) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Sanofi has a net margin of 16.95% compared to BeOne Medicines' net margin of 8.94%. Sanofi's return on equity of 13.39% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
BeOne Medicines	8.94%	12.06%	6.69%

In the previous week, BeOne Medicines had 6 more articles in the media than Sanofi. MarketBeat recorded 12 mentions for BeOne Medicines and 6 mentions for Sanofi. Sanofi's average media sentiment score of 0.54 beat BeOne Medicines' score of -0.46 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.03	$8.84B	$3.58	11.54
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	62.00

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sanofi has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Sanofi currently has a consensus target price of $51.00, indicating a potential upside of 23.40%. BeOne Medicines has a consensus target price of $390.00, indicating a potential upside of 40.73%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

Summary

BeOne Medicines beats Sanofi on 10 of the 16 factors compared between the two stocks.

How does BeOne Medicines compare to argenex?

BeOne Medicines (NASDAQ:ONC) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

argenex has a net margin of 31.31% compared to BeOne Medicines' net margin of 8.94%. argenex's return on equity of 44.37% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
argenex	31.31%	44.37%	37.55%

In the previous week, BeOne Medicines had 7 more articles in the media than argenex. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for argenex. argenex's average media sentiment score of 0.20 beat BeOne Medicines' score of -0.46 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has lower revenue, but higher earnings than BeOne Medicines. argenex is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	62.00
argenex	$4.25B	12.48	$1.29B	$22.46	37.96

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BeOne Medicines presently has a consensus target price of $390.00, suggesting a potential upside of 40.73%. argenex has a consensus target price of $1,023.39, suggesting a potential upside of 20.05%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Summary

argenex beats BeOne Medicines on 9 of the 16 factors compared between the two stocks.

How does BeOne Medicines compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, BeOne Medicines had 10 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for BeOne Medicines and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.17 beat BeOne Medicines' score of -0.46 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a net margin of 8.94% compared to Takeda Pharmaceutical's net margin of 4.31%. BeOne Medicines' return on equity of 12.06% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
BeOne Medicines	8.94%	12.06%	6.69%

BeOne Medicines has lower revenue, but higher earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.77	-$1.01B	$0.39	40.35
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	62.00

Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

BeOne Medicines has a consensus price target of $390.00, indicating a potential upside of 40.73%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

BeOne Medicines beats Takeda Pharmaceutical on 15 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

BeOne Medicines (NASDAQ:ONC) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has higher revenue and earnings than BeOne Medicines. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	62.00
Teva Pharmaceutical Industries	$17.26B	2.28	$1.41B	$1.33	25.72

In the previous week, Teva Pharmaceutical Industries had 17 more articles in the media than BeOne Medicines. MarketBeat recorded 29 mentions for Teva Pharmaceutical Industries and 12 mentions for BeOne Medicines. Teva Pharmaceutical Industries' average media sentiment score of 1.07 beat BeOne Medicines' score of -0.46 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	17 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines currently has a consensus price target of $390.00, suggesting a potential upside of 40.73%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 22.14%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities analysts plainly believe BeOne Medicines is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Teva Pharmaceutical Industries has a net margin of 9.01% compared to BeOne Medicines' net margin of 8.94%. Teva Pharmaceutical Industries' return on equity of 43.53% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Summary

Teva Pharmaceutical Industries beats BeOne Medicines on 9 of the 17 factors compared between the two stocks.

Get BeOne Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONC vs. The Competition

Export

Metric	BeOne Medicines	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.30B	$2.99B	$6.74B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	62.00	18.65	25.37	23.96
Price / Sales	5.69	341.96	530.17	107.90
Price / Cash	70.65	56.64	45.29	53.76
Price / Book	6.97	4.14	10.76	6.41
Net Income	$286.93M	$64.45M	$3.56B	$337.14M
7 Day Performance	2.58%	1.22%	0.99%	-1.06%
1 Month Performance	-10.68%	0.95%	0.79%	0.49%
1 Year Performance	3.74%	25.22%	30.25%	28.43%

BeOne Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONC BeOne Medicines	4.1189 of 5 stars	$277.12 +0.4%	$390.00 +40.7%	+3.9%	$30.30B	$5.34B	62.00	12,000
GSK GSK	3.3878 of 5 stars	$53.04 +0.3%	$53.00 -0.1%	+32.3%	$107.41B	$43.07B	13.78	66,841	Positive News Dividend Cut
SNY Sanofi	4.647 of 5 stars	$44.25 +0.3%	$51.00 +15.3%	-14.6%	$107.28B	$49.35B	12.36	74,846
ARGX argenex	4.0588 of 5 stars	$893.52 -0.6%	$1,019.50 +14.1%	+50.1%	$55.57B	$4.25B	39.78	1,863	Analyst Forecast
TAK Takeda Pharmaceutical	2.5844 of 5 stars	$15.92 +0.3%	N/A	+4.3%	$50.63B	$28.32B	40.81	47,455	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONC) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeOne Medicines (ONC) Competitors

ONC vs. GSK, SNY, ARGX, TAK, and TEVA

How does BeOne Medicines compare to GSK?

Summary

How does BeOne Medicines compare to Sanofi?

Summary

How does BeOne Medicines compare to argenex?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeOne Medicines (ONC) Competitors

ONC vs. GSK, SNY, ARGX, TAK, and TEVA

How does BeOne Medicines compare to GSK?

Does the media prefer ONC or GSK?

Which has more volatility and risk, ONC or GSK?

Which has preferable earnings and valuation, ONC or GSK?

Do analysts prefer ONC or GSK?

Is ONC or GSK more profitable?

Do insiders and institutionals hold more shares of ONC or GSK?

Summary

How does BeOne Medicines compare to Sanofi?

Is SNY or ONC more profitable?

Does the media prefer SNY or ONC?

Which has better valuation and earnings, SNY or ONC?

Do insiders and institutionals have more ownership in SNY or ONC?

Which has more risk and volatility, SNY or ONC?

Do analysts prefer SNY or ONC?

Summary

How does BeOne Medicines compare to argenex?

Is ONC or ARGX more profitable?

Does the media refer more to ONC or ARGX?

Which has stronger earnings & valuation, ONC or ARGX?

Do institutionals and insiders have more ownership in ONC or ARGX?

Do analysts recommend ONC or ARGX?

Which has more volatility and risk, ONC or ARGX?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Does the media prefer TAK or ONC?

Is TAK or ONC more profitable?

Which has stronger earnings & valuation, TAK or ONC?

Which has more risk & volatility, TAK or ONC?

Do analysts recommend TAK or ONC?

Do institutionals & insiders have more ownership in TAK or ONC?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Which has more risk & volatility, ONC or TEVA?

Do institutionals and insiders believe in ONC or TEVA?

Which has higher earnings and valuation, ONC or TEVA?

Does the media favor ONC or TEVA?

Do analysts rate ONC or TEVA?

Is ONC or TEVA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools